Research programme: sirtuin targeted therapeutics - Evrys Bio
Latest Information Update: 15 Jul 2021
At a glance
- Originator Princeton University
- Developer Evrys Bio
- Class Antivirals; Small molecules
- Mechanism of Action Sirtuin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cytomegalovirus infections; Polyomavirus infections; Viral infections
Most Recent Events
- 13 Jul 2021 Sirtuin based therapeutics development is ongoing for Polyomavirus infections, Cytomegalovirus infections
- 13 Jul 2021 Preclinical trials in Cytomegalovirus infections in USA (PO)
- 13 Jul 2021 Preclinical trials in Polyomavirus infections in USA (PO)